About Accel-Rx
Accel-Rx is a venture capital firm founded in 2014. It is primarily based out of Vancouver, Canada. As of Jul 2018, Accel-Rx has invested in 11 companies. It primarily invests in Seed round in Canada based startups. Its investments are spread across a wide range of sectors from Life Sciences to HealthTech and Real Estate and Construction Tech. Most recently it participated in the $***** Series A round of Inversago Pharma Overall, Accel-Rx portfolio has seen 1 acquisition, namely Encycle Therapeutics. A lot of funds co-invest with Accel-Rx, with names like Genesys Capital sharing a substantial percentage of its portfolio.Key Metrics
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Seed, Series A & 1 more
Portfolio Acquisitions
Portfolio Soonicorns
Accel-Rx's List of Top Investments
Accel-Rx has a portfolio of 11 companies. Their most notable investments are in Zucara Therapeutics and ScarX Therapeutics.Their portfolio spans across and Canada. They have invested in Life Sciences, HealthTech, Real Estate and Construction Tech and 4 other sectors, across stages such as Seed, Series A and 1 more. Here is the list of top investments by Accel-Rx:Flosonics Medical is a developer of non-invasive sensors for the management of critically ill patients, performing continuous monitoring of arterial flow with automatic artery detection. The company develops products for fluid responsiveness detection in the ICU, E.D, and operating room. The company's smart-bandage product, FloPatch, is designed to address the clinical needs of critically ill patients and the physicians, nurses, and paramedics who care for them in the ambulance, emergency department, operating room, and intensive care unit. The patch is disposable and is enabled with ultrasound technology.
Key facts about Flosonics Medical
- Founded Year: 2015
- Location: Greater Sudbury (Canada)
- Stage: Series C
- Total Funding till date: $39M
- Employee Count: 75 as on Sep 30, 2026
- Investors: New Leaf Venture Partners, Graphite Ventures and 15 Others
- Latest Funding Round: Venture Debt, Mar 03, 2025, $*****
- Highlight: Editors' Pick
Zucara Therapeutics, a spin-off of The Centre for Drug Research and Development (CDRD) and MaRS Innovation (MI), is developing a novel drug for the treatment of hypoglycemia associated with insulin therapy. Their lead candidate PRL-2903 works via the chronic receptor antagonism through which they block somatostatin type 2 (SSTR2) receptors on α-cells in the pancreas.
Key facts about Zucara Therapeutics
- Founded Year: 2015
- Location: Vancouver (Canada)
- Stage: Series B
- Total Funding till date: $50.8M
- Employee Count: 13 as on Sep 30, 2026
- Investors: Perceptive Advisors, Sanofi and 14 Others
- Latest Funding Round: Series B, Feb 03, 2025, $*****
- Highlight: Editors' Pick
3. Encycle
Provider of wireless energy management solutions. It offers enviro grid swarm logic controllers that are attached to electrical loads like air conditioning, heaters, compressors, pumps, humidifiers, dehumidifiers, to communicate and coordinate with each other and to reduce electrical demand for commercial, industrial, institutional, and multi-unit residential facilities.
Key facts about Encycle
- Founded Year: 2005
- Location: Toronto (Canada)
- Stage: Series C
- Total Funding till date: $46.2M
- Employee Count: 25 as on Sep 30, 2026
- Investors: NGEN Partners, MaRS Discovery District and 13 Others
- Latest Funding Round: Series C, May 12, 2021, $*****
- Highlight: Editors' Pick
Inversago Pharma (formerly GIcare Pharma) is focused on developing peripheral cannabinoid (CB1) receptor antagonist/inverse agonist for the treatment of metabolic diseases such as obesity, insulin resistance, and liver fibrosis. Its drug INV-101 (Inverse agonist of peripheral CB1) under phase-1.
Key facts about Inversago Pharma
- Founded Year: 2015
- Location: Montreal (Canada)
- Stage: Series C
- Total Funding till date: $115M
- Employee Count: 10 - 49 as on Mar 01, 2026
- Investors: Amgen Business Development, T1D Fund and 10 Others
- Latest Funding Round: Series C, Oct 17, 2022, $*****
- Highlight: Editors' Pick
5. KisoJi
Developer of multi-specific antibodies for cancer treatment. It offers tri-specific immuno-oncology antibody candidates which include KJ-101 for neuroendocrine solid tumors, KJ-102 for acute myeloid leukemia, and KJ-103 for TROP-2 Expressing solid tumors.
Key facts about KisoJi
- Founded Year: 2009
- Location: Montreal (Canada)
- Stage: Series B
- Total Funding till date: $41.3M
- Employee Count: 22 as on Sep 30, 2026
- Investors: Lumira Ventures, Invest Quebec and 5 Others
- Latest Funding Round: Series B, Oct 2024, $*****
- Highlight: Editors' Pick
Accel-Rx's Year-on-Year Investment Trends
Accel-Rx has invested in 11 companies over the last 11 years, with an average of 1 new investment annually in the last 10 years. Its most recent first time investment was in Inversago Pharma.Accel-Rx's Investments by Stage
Accel-Rx has made 5 investments in Seed stage with an average round size of $2.02M, 4 investments in Series A stage with an average round size of $3.76M and 1 investment in Series B stage with an average round size of $2.15M.Stage of entry | No. of Investments |
|---|---|
Seed | 5 |
Series A | 4 |
Series B | 1 |
Note: We have considered here, only first round of investments
Accel-Rx's Investments by Sector
Accel-Rx has a diverse portfolio, with companies operating in the Life Sciences, HealthTech, High Tech, Internet of Things - Industry Applications and Consumer. Notably, it has invested in 11 Tech companies, 7 Enterprise (B2B) companies, 4 Software companies and at least 3 companies focusing on Tech hardware.Sector | No. of Investments |
|---|---|
Life Sciences | 9 |
HealthTech | 2 |
High Tech | 2 |
Internet of Things - Industry Applications | 2 |
Consumer | 1 |
Others | 4 |
Note: We have considered here, only first round of investments
Accel-Rx's Investments by Geography
Accel-Rx has made most investments in Canada (10).Accel-Rx's recent investments
Accel-Rx has not made any investment in 2026 so far.Here are the most recent investments by Accel-Rx:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Jul 25, 2018 | Canada | Series A | 8499 | [+4] | |
Jan 29, 2018 | Canada | Seed | 9062 | [+5] | |
Nov 27, 2017 | Canada | Series A | 8494 | [+1] | |
Sep 11, 2017 | Canada | Seed | 2603 | [+1] | |
Nov 03, 2016 | Canada | Seed | 6907 | [+1] |
Acquired companies in Accel-Rx's Portfolio
1 company from Accel-Rx's portfolio has been acquired. The most recent acquisition was Encycle Therapeutics in Oct 2019 by Zealand Pharma for $*****.Here are Accel-Rx's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Oct 22, 2019 | Sep 30, 2015 | Series A | 7480 |
Co-investors of Accel-Rx
Over the past 11 years, 56 investors have co-invested in Accel-Rx's portfolio companies. This includes funds and angels.
- Invested before Accel-Rx: CQDM, Mitacs and 13 others have invested in rounds before Accel-Rx. There are 2 companies where CQDM has invested before Accel-Rx and 1 company where Mitacs has invested before Accel-Rx.
- Top Co-investors of Accel-Rx: 18 investors entered a company along with Accel-Rx. These include investors like Genesys Capital (2 companies).
- Invested after Accel-Rx: A total of 23 investors have invested in Accel-Rx's portfolio after their investments. Top Investors include adMare BioInnovations (2 companies), Arboretum Ventures (1 company) and MedTech Innovator (1 company).
Recent News related to Accel-Rx
•
Inversago Pharma Receives $7 Million in Series A FinancingBusiness Wire•Jul 25, 2018•Inversago Pharma, Genesys Capital, AmorChem, Accel-Rx and 4 others
•
FloSonics Medical seeded with $5 mln in iGan-led roundPE Hub•Jan 29, 2018•Flosonics Medical, iGan Partners, Genesys Capital, MaRS IAF and 4 others
•
•
SpecificiT Raises Seed FinancingPR Newswire•Sep 11, 2017•SpecificiT Pharma, AmorChem, Sanderling Ventures, Accel-Rx
•
ScarX Therapeutics Closes $2M Series A Financing |FinSMEsFinSMEs•Feb 18, 2016•ScarX Therapeutics, MaRS Innovation, BDC Capital, Accel-Rx
•
MaRS Innovation ScarX Therapeutics closes $2 million Series A financing - MaRS InnovationMaRS Innovation•Feb 16, 2016•ScarX Therapeutics, MaRS Innovation, BDC Capital, Accel-Rx
•
•
Encycle Therapeutics Raises $2.85 Million to Expand Development Pipeline | BetaKitBetaKit•Encycle Therapeutics, Takeda Ventures, Accel-Rx, BDC Capital and 3 others
